Capsular polysaccharides are the primary antigenic components involved in protective immunity against encapsulated bacterial pathogens. Although immunization of adolescents and adults with polysaccharide antigens has reduced pathogen disease burden, pure polysaccharide vaccines have proved ineffective at conferring protective immunity to infants and the elderly, age cohorts that are deficient in their adaptive immune responses to such antigens. However, T-cell-independent polysaccharide antigens can be converted into more potent immunogens by chemically coupling to a "carrier protein" antigen. Such "conjugate vaccines" efficiently induce antibody avidity maturation, isotype switching, and immunological memory in immunized neonates. These immune responses have been attributed to T-cell recognition of peptides derived from the coupled carrier protein. The covalent attachment of polysaccharide antigens to the carrier protein is thought to be imperative to the immunological properties of conjugate vaccines. Here we provide evidence that covalent attachment to carrier proteins is not required for conversion of T-independent antigens into T-dependent immunogens. Simple entrapment of polysaccharides or a D-amino acid polymer antigen in a cross-linked protein matrix was shown to be sufficient to produce potent immunogens that possess the key characteristics of conventional conjugate vaccines. The versatility and ease of manufacture of these antigen preparations, termed protein capsular matrix vaccines (PCMVs), will likely provide improvements in the manufacture of vaccines designed to protect against encapsulated microorganisms. This in turn could improve the availability of such vaccines to the developing world, which has shown only a limited capacity to afford the cost of conventional conjugate vaccines.
virtual polysaccharide conjugates | protein capsular complexes | T-independent antigens C apsular polysaccharides are the principal antigenic components involved in protective immunity against encapsulated bacterial pathogens including, for example, Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type b (1-7). Immunization of adolescents and adults with polysaccharide (PS) antigens from these pathogens has been successful in reducing disease burden but has proven ineffective in providing protective immunity to key vaccine cohorts, including infants, young children, and the elderly (2, (8) (9) (10) .
For children who have not yet developed a mature adaptive immune repertoire, T-independent antigens, such as capsular polysaccharides, are poorly immunogenic and do not lead to long-term protective immune responses (8) (9) (10) (11) . It is generally accepted that polysaccharide antigens do not induce T-cell help and isotype switching because they cannot be processed and presented via the major histocompatibility complex (MHC) (9) (10) (11) . T-cellindependent antigens usually generate antibodies of the low-affinity IgM isotype antibody and do not induce immunological memory, affinity maturation of B cells, or class switching to higher affinity antibodies of the IgG isotype. Direct conjugation of the polysaccharide antigen to a protein carrier changes the context in which immune effector cells respond to polysaccharides (2) . In a conjugate vaccine, B cells that recognize the polysaccharide take up the conjugate and present the processed protein portion of the vaccine to T cells via the MHC class II pathway (8) . Upon MHC class II peptide recognition by the T-cell receptor, T cells become activated and secrete cytokines that provide "help" for the induction of B-cell affinity maturation and antibody isotype switching to produce higher affinity antibodies against the polysaccharide antigen. This hypothesis is supported by the fact that coadministration of polysaccharide and protein that are not covalently attached does not result in T-cell activation (12, 13) . These data, however, do not rule out the possibility that the polysaccharide and protein only have to be close enough in proximity to be taken up by the same B cell and do not have to be covalently attached to achieve T-cell activation.
To test this idea, we synthesized and tested the immunogenicity of a novel vaccine process whereby the polysaccharide or capsular antigens were entrapped in a cross-linked protein matrix where there is minimal or no covalent linkage of the capsular antigen to the protein. We term these entrapped capsular antigens protein capsular matrix vaccines (PCMVs). The conceptual difference between a conventional conjugate vaccine and a PCMV is depicted in Fig. 1 . We demonstrate that a PCMV made with two different capsular antigens induces an anticapsular antibody response comparable to that elicited by a cognate conjugate vaccine. Furthermore, we show that a PCMV synthesized with serotype 14 polysaccharide from S. pneumoniae (PPS14) elicits isotype antibody switching and immunological memory. Additionally, we also demonstrate that PCMVs can be synthesized with an array of different "carrier," or matrix, proteins.
Significance
Conjugate vaccines have dramatically reduced the incidence of disease in infants and young children caused by encapsulated bacterial pathogens. These vaccines, however, are difficult and expensive to manufacture, deterring their widespread use. We present an alternative technology for the production of conjugate-like vaccines whereby capsular antigens are entrapped in a cross-linked protein matrix. The versatility and ease of protein capsular matrix vaccine production compared with conjugates will likely render the manufacture of these vaccines simpler and more cost effective than conjugate vaccines. This in turn would improve the availability of such vaccines to the developing world, which has shown a limited capacity to afford the cost of conventional conjugate vaccines.
Results
A PCMV Made with Bacillus anthracis Poly-Gamma-D-Glutamic Acid Capsular Antigen and a B. anthracis Protective Antigen Mutant (DNI) Matrix Protein. Preliminary studies in synthesizing and determining the immunogenicity of a PCMV were performed using the T-independent capsular antigen, poly-gamma-D-glutamic acid (PGA), and the carrier/matrix protein DNI, or dominant negative inhibitor, a mutant of the protective antigen (PA) moiety of anthrax toxin (14) (15) (16) , derived from B. anthracis. PGA is an atypical capsule in that it is a linear polypeptide generated through gamma peptide bonds of glutamic acid rather than the more common polysaccharide-based capsules (17, 18) . Furthermore, because PGA is not synthesized from a nucleic acid coding sequence, it is unclear whether this polymer displays an unblocked α-amino group at its N terminus. A PGA PCMV was synthesized by incubating PGA and DNI with glutaraldehyde to initiate crosslinking of the primary amines of DNI presumably donated by e-amino groups of lysine residues. The reaction products from one such reaction were separated by SDS/PAGE on a 10% (wt/vol) Bis·Tris gel along with DNI and PGA controls. Coomassie blue staining of the gel revealed that the PCMV reaction contained higher molecular weight material than the DNI control, indicating that the DNI in the PCMV was cross-linked into higher molecular weight forms ( Fig. 2A, Left) . High molecular weight material was also observed at the top of the wells loaded with PCMV samples. To visualize both the protein and the capsule, the DNI-PGA PCMV products were separated by SDS/ PAGE along with PGA and DNI controls and visualized using a combined Alcian blue-silver stain method ( Fig. 2A, Right) . The PGA control sample displayed a smear pattern, due to the polydispersity in polymer size, whereas a predominant single band of the appropriate molecular size was observed with the DNI control. The PCMV, however, displayed a more intense higher molecular weight staining that comigrated with the high molecular weight protein aggregates observed in the Coomassie blue stained gel. The slower electrophoretic mobility of both the PGA and DNI components in the PCMV sample indicates that the two components are likely associated in a macromolecular complex. In the context of such particles, DNI or other proteins will be hereafter referred to as "matrix proteins" to distinguish them from "carrier proteins" associated with typical conjugate vaccines that carry covalent cross-links between capsular antigens and proteins.
A capture-based ELISA was used to demonstrate that PGA was entrapped in the DNI protein matrix. In this assay, PCMV samples or controls were incubated in microtiter wells coated with anti-PA antibody to capture DNI. After washing away unbound material, PGA associated with the bound DNI was detected using anti-PGA antisera. With control samples of crosslinked DNI admixed with PGA or PGA alone, a negligible signal was detected (Fig. 2B, Top) . In sharp contrast, the PCMV sample showed a strong, positive, titratable signal, which at its peak was about 20-fold greater than the control samples. These data indicate that PGA, in the PCMV sample, was associated with the bound DNI matrix. When anti-PA (DNI) was used as the detection sera, samples containing DNI (the PCMV sample and cross-linked DNI control) showed similar signals (Fig. 2B,  Bottom) , indicating similar amounts of DNI were bound to the capture antibody.
Immunization with PGA-DNI PCMV Elicits Anti-PGA-Specific IgG Antibodies. To determine if the DNI-PGA PCMV was immunogenic, three groups of BALB/c mice (n = 5 per group) were immunized intraperitoneally (i.p.) three times at 10-12-d intervals with either PGA-DNI PCMV reaction products, un-cross-linked DNI and PGA (admixed control), or DNI protein only. One week after each immunization, blood was collected and sera from each group of mice were pooled to determine the magnitude of anti-PGA IgM and IgG antibody responses (Fig. 2C) . Anti-PGA IgM antibody responses increased after each immunization with the DNI-PGA PCMV. No increase in IgM antibody response was observed with the admixed control, DNI control, or naïve animals. The anti-PGA-specific IgG antibody responses increased over time only in mice immunized with the DNI-PGA PCMV. Anti-PGA IgG antibody was undetectable in sera from naïve animals and those immunized with the admixed control or DNI protein control.
Effect of Varying Matrix Protein Carriers on PGA-Based PCMVs. To assess whether the immune response to PGA is influenced by the matrix protein and to determine if different proteins can be used in PCMV reactions, groups of mice were immunized with PGAbased PCMV reactions synthesized with either BSA, diphtheria toxin (DT), or tetanus toxoid (TTx). All of the PCMVs synthesized with the various matrix proteins elicited anti-PGA IgG antibody titers that were greater than naïve mice, however the matrix proteins used affected the magnitude of the immune response. PGA-based PCMVs synthesized with BSA, DT, or TTx PCMVs eliciting geometric mean titers (GMTs) of 4,850, 3,676, and 19,401, respectively (Fig. 2D ).
PCMV Technology Application to a Capsular Polysaccharide Antigen.
Because PGA is not a polysaccharide-based capsule antigen, we wanted to determine whether the immune response elicited by a PCMV could be enhanced with a polysaccharide capsule. PCMV particles were made with pneumococcal polysaccharide serotype 14 (PPS14) as the capsule antigen and DNI, diphtheria toxoid (DTx), or TTx as matrix proteins. Serotype 14 repeating unit contains, in theory, no primary amines. When PPS14 was assayed for the presence of primary amines using 2,4,6-trinitrobenzene sulfonic acid (TNBS) (19) , no detectable signal was observed. Based on the lowest detectable standard in the TNBS assay, the PPS14 preparations used contained less than two primary amines per 1.1 MD polysaccharide molecule (corresponding to nearly 7,000 monosaccharide repeats). Thus, we predict that little if any covalent cross-links can occur between PPS14 and matrix proteins based on the presence of amines in PPS14. We cannot discount the possibility that reducing sugars that may occur on the very end of the large PPS14 polymer could form Schiff bases with amino groups of carrier proteins. However, such conjugates would contain, stoichiometrically, a very small amount of matrix protein and would have been undetectable by capture ELISA.
Mice were immunized i.p. three times at biweekly intervals with PPS14 PCMVs synthesized with the three different matrix proteins. The PPS14 PCMVs were adjuvanted with aluminum hydroxide and anti-PPS14 antibody levels determined 2 wk after third immunization (Fig. 3A) . Consistent with the PGA capsular antigen PCMV results, the PPS14 PCMVs synthesized with the three different matrix proteins elicited IgG antibody responses greater than naïve mice, and likewise, the magnitude of the immune response varied among the different matrix proteins used. These data indicate that a diverse range of proteins can be used to form the protein matrix and that PCMVs made with capsular polysaccharides are highly immunogenic. Further, the choice of matrix protein influences the magnitude of the antibody response directed against the capsular antigens.
PCMV-Induced Anti-PPS14 Antibodies Mediate Opsonophagocytosis.
To determine whether the antibodies elicited by a PPS14 PCMV are functional and capable of opsonizing the bacteria and mediating phagocytosis, we synthesized a PPS14 DNI PCMV and immunized mice i.p. three times at biweekly intervals. Sera were collected 2 wk after the third immunization. Different amounts of sera [25% and 12.5% (vol/vol)] from mice immunized with PPS14 PCMV were incubated with S. pneumoniae serotype 14 bacteria. Serotype 14 bacteria were subsequently incubated with macrophage cell line RAW264.7 cells and the intracellular bacteria enumerated. Fig. 3B shows that sera from mice immunized with the PPS14 PCMV-elicited antibodies were able to opsonize bacteria and enhance uptake into macrophages about 40-fold greater than naïve sera [25% (vol/vol)] and PBS controls. Size Fractionation and Characterization of PPS14 DNI PCMV. All immunizations described previously were performed using the entire PCMV reaction mixture, which contains PPS14-DNI PCMV product, untrapped PPS14, DNI protein, and cross-linked DNI protein.
To determine if improved immunogenicity could be observed by removing unreacted components and enriching for polysaccharide entrapped in the protein matrix, PCMV reactions were separated by size exclusion chromatography on a Sepharose CL-2B column (Fig. 4A) . The fractions containing high molecular weight material that eluted in the void volume of the column and lower molecular weight species were used to generate pool 1 and pool 2, respectively. Using size exclusion chromatographymultiangle laser light scattering (SEC-MALLS) analysis, the particle size of the material in pool 1 ranged from 120 to 200 nm in diameter, whereas the particles in pool 2 averaged 63 nm in diameter. Analysis of pools 1 and 2 by SDS/PAGE and Coomassie blue staining showed that pool 1 contained very high molecular weight material that did not migrate into the separating portion of the gel, whereas pool 2 and the unfractionated whole reaction PCMV sample contained lower molecular weight material that migrated into the gel (Fig. 4B ).
To determine if the material in pools 1 and 2 contained entrapped PPS14 polysaccharide, a DNI-based capture ELISA was performed, in which samples are bound or captured to a microtiter plate via antibodies to DNI. As controls, unfractionated DNI-PPS14 PCMV, cross-linked DNI admixed with PPS14, and PPS14 alone were analyzed. All samples, except the PPS14-alone control, reacted when the bound material was probed with anti-DNI antibody (Fig. 4C) . The difference in signal between pool 1, pool 2, unfractionated PCMV, and admixed DNI and PPS14 is likely due to the difference in the globular nature of the crosslinked protein in each vaccine. When captured material was probed with anti-PPS14 detection antibody, PPS14 was detected only in pools 1 and 2, suggesting that the polysaccharide is entrapped in the DNI matrix (Fig. 4D ). As expected, there was negligible detection of PPS14 in cross-linked DNI admixed with PPS14. Interestingly, there was negligible signal with the unfractionated PCMV reaction mixture. This is likely due to the un-crosslinked DNI in the PCMV reaction mixture competing with the PPS14 DNI PCMV for the capture antibody. Overall, the DNI capture ELISA demonstrated entrapment of PPS14 within the cross-linked DNI protein matrix and that PPS14 is surface exposed in the context of the PCMV matrix.
Size-Fractionated PPS14-DNI PCMV Induces High-Titer Anti-PPS14 Antibody Responses. To determine the immunogenicity of the two PPS14-DNI PCMV pools shown in Fig. 4A , mice were injected i.p. with aluminum hydroxide-adjuvanted material three times at biweekly intervals. As controls, groups of mice were immunized i.p. with the unfractionated PCMV reaction products or PPS14 polysaccharide. The 5-μg dose for pool 1, pool 2, and unfractionated PCMV was based on protein amount in the sample, whereas the PPS14 control was based on the polysaccharide amount. Sera were collected 10 d after the third immunization for determination of anti-PPS14-specific IgG titers by ELISA. Sera from mice immunized with 5 μg of pool 1, pool 2, or the unfractionated PPS14 DNI PCMV reaction mixture contained 16.7-, 7.1-, and 2.3-fold higher anti-PPS14-specific IgGs, respectively, than sera from mice that were immunized with PPS14 polysaccharide alone (Table 1) . Interestingly, sera from animals immunized with pool 1, which contained half the amount of polysaccharide of pool 2, was 2.3-fold more immunogenic. This increase in immunogenicity may be due to the larger particle sized PCMV in pool 1.
Because PPS14 is an inherently immunogenic polysaccharide, mice were immunized with a lower dose of PPS14 alone (2 μg PPS14) and pool 1 (2 μg DNI, 0.95 μg PPS14) to compare the immune response. The lower dose of pool 1 elicited anti-PPS14 IgG titers that were >127-fold higher than sera from mice immunized with 2 μg PPS14 polysaccharide alone, however the GMT for pool 1 at the lower dose was only slightly lower than that observed at the higher dose (GMT 182,127 versus 135,148) (Table 1) . Collectively, these data demonstrate that size fractionation of the PCMV products and immunization of animals with larger sized (∼120-200 nm) particles elicit high-titer anti-PPS14-specific IgG antibody responses.
Immunization with PPS14 PCMV Induces a Long-Term Anti-PPS14 Anamnestic Antibody Response. One key advantage of polysaccharide-protein conjugate vaccines over polysaccharide vaccines is the ability of conjugate vaccines to produce immunological responses that elicit high antibody titers that are anamnestic in nature (3). To determine whether PCMV immunization is able to elicit long-term anamnestic, or memory, immune responses, we collected additional sera from mice immunized with the two PPS14-DNI PCMV pools or PS alone after 7-8 mo to determine when anti-PPS14 IgG titers began to decline. Sera were collected 239 d following the initial immunization regimen, and mice were immunized with either DNI-PPS14 PCMV or PPS14, homologous boost, as indicated in Table 2 . Sera were collected 4 d after the booster immunization (day 243) and 3 wk after the boost (day 260) to determine the PPS14-specific IgG response.
A B with PPS14 PCMVs synthesized using DNI, DTx, and TTx elicited variable but significant anti-PPS14 antibody responses. Anti-PPS14 IgG GMTs were determined using an ELISA on pooled sera collected from mice immunized with a PPS14 PCMV. (B) RAW264.7 cells were incubated with S. pneumoniae serotype 14 that had been preincubated with 25% or 12.5% sera from PPS14 PCMV immunized mice, 25% naïve sera, or PBS. Wells were washed three times with PBS to remove nonphagocytized bacteria, and the macrophage cells containing internalized bacteria were lysed using 1% saponin diluted in PBS. Lysates were plated onto blood agar plates for enumeration of cfus that had been internalized. The fold increase in opsonophagocytosis for bacteria incubated with PCMV immune sera and naïve sera was calculated by dividing the internalized cfus from each group by the cfus obtained from the PBS control.
The PPS14-specific IgG antibody level remained relatively high 7 mo following the initial PPS14-DNI PCMV immunization regimen. The anti-PPS14 IgG GMT at day 239 for the 2-and 5-μg doses were 152,691 and 334,531, respectively (Table 2) . After immunizing at day 239, a sharp increase of PPS14-specific IgG antibodies was observed 4 d postboost only in PCMVimmunized animals (GMT of 266,251 or 408,445 for 2-μg and 5-μg doses, respectively) compared with PPS14-only immunized animals ( Table 2 ). Titers increased significantly 3 wk postboost in PCMVimmunized mice (GMT of 816,890 or 863,756 for 2-μg and 5-μg doses, respectively), whereas PS-immunized mice developed either no or a minimal increase in anti-PPS14-specific IgG antibody titer.
To further explore whether PCMV-formulated PPS14 elicits a T h memory response, the IgG:IgM ratio was determined. Polysaccharide-alone vaccines typically elicit IgM and low levels of IgG, whereas polysaccharide-protein conjugate vaccines elicit substantially higher levels of IgG (11, 20) . Results demonstrate that immunization with PPS14 induced an antibody response with an IgG:IgM ratio of ∼1:1 (Fig. 5) . In contrast, mice immunized with PPS14-DNI PCMV pool 1 and pool 2 elicited significantly more IgG compared with IgM with ratios of IgG:IgM of ∼10-100:1 (Fig. 5) . The PPS14 PCMV fractionation experiment described above directly compared the immunogenicity of PCMV-sized particles to PPS alone. A PCMV using DNI as the matrix protein and PPS14 as the capsular polysaccharide was synthesized using similar reaction conditions as above. The PCMV was fractionated by SEC on a Sepharose CL-2B column into the four pools indicated in Fig. 6A .
Size-fractionated PPS14 PCMV pools 1-4 were characterized using the DNI capture ELISA to determine the relative level of PPS14 entrapment and surface exposure (Fig. 6 B and C) . PPS14 was detected in all pools; however, less PPS14 was detected in pool 4, suggesting that there was either reduced entrapment or surface-exposed PPS14. As expected, no PPS14 signal was detected in the cross-linked DNI admixed with PPS14 (Fig.  6B) . A similar amount of captured DNI was detected in pools 1-4 and the cross-linked DNI control when probed with anti-DNI antibody (Fig. 6C ). Together these data indicate that PPS14 is entrapped in all four pools of the size-fractionated PPS14-DNI PCMV.
Fractionated PCMV (2 μg DNI or 0.5 μg DNI) of pools 1-4 or PPS14 alone were used to immunize mice. Fractionated PCMV pools were adjuvanted with aluminum hydroxide, and mice were injected i.p. three times at biweekly intervals. A group of mice was also immunized with Prevnar 7, which contains 2 μg of PPS14 in addition to six other PPSs and 20 μg CRM197 carrier Chromatogram of PCMV reaction products on a 25-mL Sepharose CL-2B column. Shown in blue is the UV 280 trace of the PCMV reaction products. The gray shaded areas indicate the fractions that were used for pool 1 and pool 2. The particle size range was determined by SEC-RI-MALLS and is indicated above each pool. (B) Simply blue Coomassie staining of a 10% SDS/PAGE gel demonstrates that pool 1 contains very high molecular weight particles that do not migrate into the gel, whereas pool 2 contains a broader distribution of particles that are able to migrate into the gel. (C and D) DNI Capture ELISA shows association of capsule with protein in PPS14-DNI pool 1 and pool 2. We coated 96-well plates with rabbit anti-DNI capture antibody, and dilutions of PCMVs from pool 1, pool 2, the unfractionated PCMV reaction (Rxn Mix), and controls (Admix, admixed cross-linked DNI plus PPS14; and PPS14) were added to the wells. After washing off unbound material, either mouse anti-DNI antisera (C) or anti-PPS14 antisera (D) were added to the wells. Bound antisera were visualized with alkaline phosphatase-conjugated secondary antibody and p-nitrophenol phosphate.
protein. In addition, the unfractionated PCMV reaction product mixture, from which the pools were derived, was also evaluated for immunogenicity. The PPS14-specific IgG response 10 d after the third, and final, immunization (day 38) was measured by ELISA and calculated as reciprocal GMTs. Consistent with the initial fractionation study in Table 1 , sera from mice immunized with pools 1-3 had markedly higher PPS14-specific IgG responses than sera from mice immunized with PPS14 alone (50-, 47-, and 20-fold greater than the PS control, respectively) ( Table 3) . Sera from mice immunized with PCMV pool 1 (2 μg DNI, 0.12 μg PPS14) and pool 2 (2 μg DNI, 0.22 μg PPS14), which likely contain larger sized particles and less unincorporated free polysaccharide, elicited anti-PPS14 IgG antibody titers comparable to that induced by Prevnar 7 (Table 3) . It is important to note that the actual dose of PPS14 in PCMV pools was substantially less than the dose of PPS14 contained in Prevnar 7 (∼17-fold less for pool 1, ninefold less for pool 2, and fourfold less for pool 3). Collectively, our data suggest that the PPS14-specific IgG titers induced by immunization with fractionated PCMV particles were comparable to those induced by much higher levels of antigen present in Prevnar 7 and were substantially higher that those induced by PPS14 polysaccharide alone.
Discussion
Polysaccharides and organic polymers, such as PGA, are classic T-independent antigens (3, 10) . These antigens typically elicit low-affinity IgM-dominated humoral immune responses and no memory. The hallmarks of T-dependent immune responses elicited by conventional conjugate vaccines are polysaccharidespecific isotype switching from IgM to IgG, B-cell maturation, and long-lived memory, or anamnestic, immune responses (2). It has been thought that polysaccharide conjugate vaccines are able to elicit T-cell help by processing and presentation of the protein carrier component to T cells leading to T-cell-dependent activation and maturation of polysaccharide-specific B cells (21) . Although covalent coupling of capsular polymers such as polysaccharides to carrier proteins was previously thought to be required for the enhanced immunogenicity of conjugate vaccines, here we demonstrate that "association" may be the key requirement. The PCMV immunogens we describe here do not have capsular polymers covalently linked to a protein carrier but rather depend on capsular polymers being stably entrapped in a cross-linked protein matrix. We demonstrate that these PCMV immunogens elicit immune responses that are comparable to conjugate vaccines despite the absence of covalent bonding between the polysaccharide (or poly D-amino acid polymer) and the matrix protein. PCMV immunogens also induce antibodies that undergo antibody isotype switching, affinity maturation, and memory responses that are typically triggered by immunization with a conjugate vaccine but not by T-independent antigens such as most capsular polysaccharides.
Recently, Avci et al. (21) showed that one way a PS-protein conjugate vaccine might elicit T-helper responses is by presentation to T-helper cells of the carbohydrate antigen covalently conjugated to a peptide on MHCII. Mice primed with type III polysaccharide from group B Streptococcus conjugated to a protein carrier and then boosted with the conjugate demonstrated an antipolysaccharide IgG response that was not observed when mice were boosted with polysaccharide alone, unconjugated type III polysaccharide mixed with protein, or by carrier protein alone. The authors show that the type III polysaccharide was detected on antigen-presenting cells only when this polysaccharide antigen was covalently coupled to a protein carrier. This study suggests that the antipolysaccharide immune response induced by type III polysaccharide-protein conjugates is a function of antigen processing and presentation of fragments of the polysaccharide-protein conjugate on MHCII to T-helper cells. Although this is one mechanism by which T-cell help may be activated by a polysaccharide-protein conjugate antigen, the results presented in our PCMV studies suggest that there are other pathways for eliciting T-cell help that do not require polysaccharides to be covalently coupled to carrier proteins. A recent report by Zhang et al. (22) supports this conclusion. In this case, immunogens that had properties comparable to conjugate vaccines were prepared by noncovalently binding an avidin-related carrier protein to a biotin-modified polysaccharide. Comparable to a PCMV, this noncovalent association between polysaccharide and protein was effective at eliciting a T-dependent immune response. Thus, more work will be needed to define the presentation pathway for "virtual conjugate vaccines" such as PCMV particles and the immunogens prepared by Zhang et al. (22) .
Collectively, our data suggest (i) PCMV reactions formulated at higher concentrations of reactants where products are shifted to higher molecular weight species entrap polysaccharide more efficiently; (ii) shifting the reaction to larger size particles substantially enhances immunogenicity, even when particles contain very low amounts of polysaccharide; and (iii) size fractionation of the PCMV reaction and immunizing animals with the larger size particles can induce enhanced anti-PPS-specific IgG Groups of five mice were immunized with fractionated pool 1, pool 2 (Fig. 4A) , the unfractionated PCMV reaction products (PCMV reaction), or PPS14 three times on days 0, 14, and 28. Mice received either 5 μg or 2 μg of the PPS14 PCMV dosed by DNI protein (the amount of PPS14 indicated in table). Sera were collected 10 d after the third immunization (day 38) and the amount of anti-PPS14 IgG antibody GMT determined by ELISA. Groups of five mice were immunized i.p. three times on days 0, 14, and 28 and dosed with 5 μg DNI protein. The amount of PPS14 present in each dose is indicated. On day 239, groups of mice were homologously boosted with either PPS14 PCMV or PPS14. Anti-PPS14 IgG GMTs were determined preboost (day 239) and 4 d (day 243) and 3 wk (day 260) postboost.
antibody responses that are comparable to the responses induced by conventional conjugate vaccines. Although the studies presented in this report involve PCMVs that incorporate a single capsular antigen into a PCMV particle, we have recently established that multiple distinct capsular antigens can be entrapped in the same PCMV simultaneously (23) . Such multivalent PCMV preparations may further validate this promising approach to making complex immunogens that have properties analogous to multivalent conjugate vaccines, where individual conjugate reactions must be separately synthesized and then mixed together (24) .
Unlike other approaches for synthesis of virtual conjugate vaccines such as the one described by Zhang et al. (22) , the PCMV procedure does not require any covalent modifications of polysaccharides and therefore is predicted to neither introduce chemical linkages that alter polysaccharide epitopes nor introduce neo-epitopes (e.g., biotin) that may engender unfavorable immune responses following immunization. Thus, it is anticipated that antibiotin antibodies will be induced by the Zhang et al. (22) virtual conjugate approach.
Furthermore, the PCMV approach is predicted to invoke T-cell help using any immunogenic matrix protein, whereas other procedures (22) require binding proteins such as rhizavidin, whose safety as immunogens has yet to be established in human subjects. Thus, PCMV immunogens offer many practical and theoretical advantages over both conventional and virtual conjugate vaccines that have been previously reported and characterized. Because the prohibitive cost-of-goods of conventional conjugate vaccines have limited their expanse to much of the developing world (24), we envision that the PCMV technology described here will provide a low-cost alternative for creating a new generation of immunogens directed against encapsulated microorganisms.
Materials and Methods
Reagents. The DNI mutant of B. anthracis PA (14) was contributed by J.J.M. PGA, the capsule antigen of B. anthracis, was a gift from Julia Y. Wang, Channing Laboratories, Harvard Medical School, Boston. DT and rabbit antibody raised against PA from B. anthracis were a gift from John Collier, Harvard Medical School, Boston. DTx and TTx were obtained from Massachusetts Public Health Laboratories, and BSA was from VWR International. PPS14 was obtained from American Type Culture Collection (ATCC). Glutaraldehyde was purchased from EMD Millipore, and sodium cyanoborohydride was from Pierce. Prevnar 7 was purchased from Wyeth Pharmaceuticals.
PCMV Reactions. PCMV reactions were done by mixing protein (i.e., DNI, DT, DTx, TTx, or BSA) and a capsular antigen (i.e., PGA or PPS14) in 10 mM sodium phosphate buffer pH 7.0 in a 1-mL reaction volume. To initiate cross-linking of the protein component and entrapment of the capsular antigen, glutaraldehyde was added to the capsule-protein mixture at a final concentration of 0.25-1%. The reaction was allowed to proceed for 1-23 h at room temperature or 4°C. Reactions were terminated by the addition of sodium cyanoborohydride and incubating for 1 h at room temperature. Reaction mixtures were then dialyzed against PBS for 18-24 h using a 3,500-Da molecular weight cutoff membrane. PCMV reactions that were size fractionated were incubated for 23 h at 4°C with 0.25% glutaraldehyde and terminated and processed as described above.
SEC of PCMV Reaction Products. PCMV reaction mixtures were chromatographed through either a 25-mL or 100-mL Sepharose CL-2B column using -4) , or cross-linked DNI + PPS14 (Admix) were added to the wells. After washing off unbound material, either mouse anti-PPS14 antisera (B) or anti-DNI antisera (C) were added to the wells. Bound antisera were visualized with alkaline phosphataseconjugated secondary antibody and p-nitrophenol phosphate. a 10-mM sodium phosphate buffer pH 7.4 containing 150 mM NaCl. Fractions were collected and analyzed for protein concentration using the micro-BCA assay kit (Pierce, Inc.) and for polysaccharide content using the anthrone assay (25, 26) .
The particle size range was determined by SEC with refractive index (RI) and MALLS (27, 28) using a TSKGel G4000 SWXL column (Tosoh Biosciences, Inc.), an Agilent 1260 HPLC system, a Wyatt Optilab T-rEX RI detector, and a Wyatt DAWN HELEOS II MALLS detector. Light scattering data were processed using Wyatt ASTRA software.
SDS/PAGE Characterization of PCMV. PGA, DNI, and PGA-DNI PCMV were separated by SDS/PAGE on a 10% Bis·Tris gel (Invitrogen). To detect the capsule and protein components, the gel was fixed with 0.1% Alcian blue in 3% acetic acid (pH 2.5) for 30 min and then destained with 3% acetic acid for 30 min (29) . The gel was washed with 30% EtOH, and the silver staining procedure was performed using the SilverQuest Staining Kit (Invitrogen) according to the manufacturer's instructions starting at the sensitizing solution step. PPS PCMV particles were visualized by staining with Commassie Blue using Simply Blue Stain (Invitrogen) after SDS/PAGE. DNI Capture ELISA. Immulon 4HB microtiter plates (VWR) were coated with polyclonal rabbit antibody raised against B. anthracis PA. Dilutions of cross-linked PCMV particles or un-cross-linked formulations were added to the coated plates. Unbound protein and capsular antigen were washed away, and captured material was detected by incubation with either mouse anti-PPS-or anti-PGA-containing serum made as described below by immunizing mice three times at biweekly intervals i.p. with PPS-PCMV or PGA-PCMV or Prevnar 7. Plates were washed to remove unbound antibody and incubated with anti-mouse IgG conjugated to alkaline phosphatase (Sigma). The amount of bound material was quantified by adding 1 mg/mL p-nitrophenyl phosphate (PNPP) in 0.2 M Tris buffer (Sigmafast tablets from Sigma) to each well and measuring the absorbance at 405 nm.
Murine Immunizations. Five-to seven-week-old female BALB/c mice were obtained from Charles River Laboratory. All mice were housed using sterile set-ups and were allowed to acclimatize for 1 wk before initiation of experiments. The methods for animal experimentation were approved by both the Harvard and Boston University Medical Center Institutional Care and Use Committees.
During initial PGA-DNI PCMV experiments, groups of five BALB/c mice were immunized by i.p. injection with PGA-DNI PCMV, admixed DNI protein and PGA, or DNI protein control three times at 10-12-d intervals. One week after each immunization, blood was collected from the tail vein of each mouse and sera from each group of mice were pooled for determination of anti-DNI and anti-PGA antibody titers.
In subsequent experiments, preimmune sera from groups of 5-8 BALB/c mice were collected before initiation of immunization at the submandibular site using Goldenrod animal lancets. Groups of mice were then immunized i.p. three times at biweekly intervals with PCMV adsorbed to aluminum hydroxide (Sigma), polysaccharide alone, or Prevnar 7. Dose was determined by protein quantity. Two to three weeks after the third and last immunization, all animals were euthanized and sera collected by cardiac puncture.
Anamnestic response studies involved groups of mice that were immunized as described above. Following the third immunization, animals were bled at regular intervals throughout an 8-mo period. After 8 mo, mice were homologously boosted with either PCMV or polysaccharide. Mice were bled before the boost and then 4 d postboost by submandibular route, and all animals were euthanized 3 wk postboost. For the terminal bleed, blood was collected by cardiac puncture. Blood obtained by tail vein, submandibular, or cardiac puncture routes was allowed to clot overnight at 4°C in serum separator blood collection tubes (BD Biosciences). Blood was then centrifuged according to the manufacturer's instructions and serum collected and stored at -20°C until ready for analysis. The amount of polysaccharide antigen-specific antibody present in the blood was determined by ELISA.
Opsonophagocytosis Assay. This assay was adapted from a method described previously by Sukumar et al. (30) . Approximately 2 × 10 6 cfus of S. pneumoniae serotype 14 (ATCC) were incubated with heat-inactivated PPS14-DNI PCMV immune serum (25% or 12.5% serum diluted in PBS), naïve serum (25% serum diluted in PBS), or PBS in a 100-μL volume at 37°C, 5% CO 2 for at least 30 min in wells of a 96-well plate. Opsonized bacteria were then incubated for 1 h with 2 × 10 5 RAW264.7 cells per well plated the day before in DMEM + 10% FBS + 4 mM L-Glutamine (Invitrogen) in a 24-well tissue culture plate. Nonphagocytized bacteria were killed by adding gentamicin to a final concentration of 100 μg/mL and incubating for 1 h at 37°C in a 5% CO 2 atmosphere. After washing the wells three times with PBS to remove nonphagocytized bacteria, the macrophage cells containing internalized bacteria were lysed using 1% saponin (Mallinckrodt Chemicals) diluted in PBS. The lysates were plated onto blood agar plates (VWR) for enumeration of cfus that had been internalized. The fold increase in opsonophagocytosis for bacteria incubated with PCMV immune sera and naïve sera was calculated by dividing the internalized cfus from each group by the cfus obtained from the PBS control.
PGA-and DNI-Specific Antibody Assays. Serum samples from groups of immunized mice were analyzed for antigen-specific IgG by ELISA adapted from methods described previously (14) . Immune sera were serially diluted in PBS-0.05% Tween 20 and added to Immulon 4HB microtiter plates (VWR International) precoated overnight at 4°C with 1 μg PGA in 100 μL PBS per well or 1 μg DNI in 0.1 M sodium carbonate buffer (pH 9.5) per well. Following incubation for 16 h at 4°C with immune serum, wells were washed four times with PBS-0.05% Tween 20 and then incubated with rabbit anti-mouse gamma-chain-specific IgG conjugated to alkaline phosphatase (Sigma) to determine serum anti-PGA or DNI IgG antibody levels. Plates were visualized by the addition of 100 μL per well of 1 mg/mL PNPP in 0.2 M Tris buffer (Sigmafast tablets from Sigma) to each well and quantitated by reading the absorbance at 405 nm. Data are reported as reciprocal GMT, with the endpoint titer cutoff calculated as the absorbance value that is 2 SDs above the mean of the negative control.
PPS-Specific Antibody Assays. Serum samples from groups of immunized mice were analyzed for antigen-specific IgG by ELISA adapted from methods described preciously by Khan et al. (31) . For PPS-specific ELISAs, immune sera were serially diluted in PBS-0.05% Tween 20 containing 10 μg/mL pneumococcal cell wall polysaccharides, CWPS Multi (MiraVista Diagnostics/Statens Serum Institut), which is a mixture of CWPS1 and CWPS2. CWPS-adsorbed immune sera were added to Immulon 4HB microtiter plates (VWR International) coated 16-20 h with 100 μL per well of 5 μg/mL PPS antigen diluted in PBS. Following incubation for ∼16 h at 4°C with immune serum, wells were washed four times with PBS-0.05% Tween 20 and then incubated with 100 μL per well of biotinylated goat anti-mouse gamma-chain-specific IgG (Sigma) followed by addition of 100 μL per well of streptavidin conjugated to alkaline phosphatase (BD Biosciences). IgM levels were similarly determined using biotinylated goat anti-mouse μ-chain-specific IgM as the detection antibody followed by incubation with streptavidin conjugated to alkaline phosphatase. Plates were developed by the addition of 100 μL per well of 1 mg/mL PNPP in 0.2 M Tris buffer (Sigmafast tablets from Sigma) and quantitated by reading absorbance at 405 nm. Data are reported as reciprocal GMT, with the endpoint titer cutoff calculated as the absorbance value that is 2 SDs above the mean of the negative control.
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